A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Kamble, Sonal
- From Darkness to Light : Clinical Insights on Melatonin
Authors
1 Medical & Regulatory Affairs, Aristo Pharmaceuticals Private Limited, 23-A Shah Industrial Estate, Andheri, Mumbai, IN
2 Scientific Department, Aristo Pharmaceuticals Private Limited, IN
Source
The Indian Practitioner, Vol 74, No 8 (2021), Pagination: 30-36Abstract
Melatonin also known as ‘sleep hormone’ is synthesized and released from the pineal gland in response to the luminous information. Melatonin primarily contributes to the regulation of biological rhythms and induction of sleep. Apart from this, due to its inherent anti-oxidant property, it is known to impart protection to various tissues. In addition, it also exhibits multiplicity of physiological effects all over the body. At therapeutic level, Melatonin is used for the management of primary as well as secondary sleep disorders, jet lag, and synchronization of cardiac rhythms. Additionally, due to its pleiotropic benefits it is used in various disorders.Keywords
Melatonin, Sleep Disorders, Pleiotropic Benefits, Therapeutic Benefits.References
- Chowdhury I, Maitra S. Melatonin: Fifty Years of Scientific Journey from the Discovery in Bovine Pineal Gland to Delineation of Functions in Human, Indian Journal of Biochemistry & Biophysics.2008; 45:289-304.
- Pevet P. Melatonin Dialogues in Clinical Neuroscience. 2002; 4:57-72.
- Tordjman S, Chokron S, Delorme R, et al. Current Neuropharmacology. 2017; 15:434- 443.
- Emet M, Ozcan H, Yayla M, et al. A Review of Melatonin, Its Receptors and Drugs. Eurasian J Med. 2016; 48:135-41.
- Feingold KR, Anawalt B, Boyce A, et al. Physiology of the Pineal Gland and Melatonin – Endotext. 2000.
- Srinivasan V, Trahkt I, Spence D, et al. Melatonin and melatonergic drugs on Sleep: possible mechanisms of action. International Journal of Neuroscience. 2009; 119:821-846.
- Khullar A. The Role of Melatonin in the Circadian Rhythm Sleep-Wake Cycle. Psychiatric Times. 2012; 29:1-8.
- Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation British Journal of Pharmacology. 2018; 175:3190–3199.
- ZizhenXie, Fei Chen, William A, et al. A review of sleep disorders and melatonin. Neurological Research. 2017:1-8.
- Shechter A, Lespérance P, Ying Kin N, et al. Nocturnal polysomnographic sleep across the menstrual cycle in premenstrual dysphoric disorder Sleep Med. 2012;13:1071–1078.
- Scheer F, Morris C, Garcia J, et al. Repeated Melatonin Supplementation Improves Sleep in Hypertensive Patients Treated with Beta-Blockers: A Randomized Controlled TrialSleep. 2012; 35:1395–1402.
- Lemoine J, Nir T, Laudon M, et al. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res. 2007; 16:372-380.
- Luthringer R, Muzet M, Zisapel N, et al. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia IntClinPsychopharmacol. 2009; 24:239-249.
- Wade A G, Ford I, Crawford G, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin. 2007; 23:2597-2605.
- Roberto C, Mendonça L, Nicolas A, et al. The benefits of four weeks of melatonin treatment on circadian patterns in resistance-trained athletes. Chronobiology International. 2015; 32:1125–1134.
- Mundey K, Benloucif S, Harsanyi K, et al. Phase-Dependent Treatment of Delayed Sleep Phase Syndrome with Melatonin. Sleep. 2005; 28:1271-1278.
- Dahlitz M, Alvarez B, Vignau J, et al. Delayed sleep phase syndrome response to melatonin. Lancet. 1991; 337:1121-1124.
- Kayumov L, Brown G, Jindal R, et al. A Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effect of Exogenous Melatonin on Delayed Sleep Phase Syndrome. Psychosom Med. 2001; 63:40e8.
- Haghighi K S, Aminian O, Pouryaghoub G, et al. Efficacy and hypnotic effects of melatonin in shift-work nurses: double-blind, placebo-controlled crossover trial J Circadian Rhythms. 2008; 6:1-5.
- Sack R, Auckley D, Auger R, et al. Circadian Rhythm Sleep Disorders: Part I, Basic Principles, Shift Work and Jet Lag Disorders. Sleep. 2007; 30:1460-83.
- Herxheimer A, Petrie K. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev. 2002:1-9.
- Petrie K, Dawson A, Thompson L, et al. A Double-Blind Trial of Melatonin as a Treatment for Jet Lag in International Cabin Crew. Biol Psychiatry. 1993; 33:526-30.
- McCarter S, Boswell C, St. Louis E, et al. Treatment outcomes in REM sleep behavior disorder. Sleep Med. 2013; 14:237–242.
- McGrane I, Leung J, St. Louis E, et al.Melatonin therapy for REM sleep behavior disorder: a critical review of evidence. Sleep Med. 2015; 16:19–26.
- Kunz D, Mahlberg R. A two-part, double-blind, placebocontrolled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res. 2010; 19:591-596.
- Sack R, Brandes R, Kendali A, et al. Entrainment of freerunning circadian rhythms by melatonin in blind people. N Engl J Med. 2000; 343:1070-1077.
- Hack L, Lockley S, Arendt J, et al. The Effects of Low-Dose 0.5-mg Melatonin on the Free-Running Circadian Rhythms of Blind Subjects. J Biol Rhythms.2003;18:420-429.
- Rockville. AHRQ Evidence Report Summaries. Agency for Healthcare Research and Quality (US); 1998-2005.
- Tian Li, Shuai J, Mengzhen H, et al. Exogenous melatonin as a treatment for secondary sleep disorders: a systematic review and meta-analysis Front Neuroendocrinol. 2019; 52:22-28.
- Cardinali D, Brusco L, Liberczuk C, et al. The use of melatonin in Alzheimer’s disease. Neuro Endocrinol Lett. 2002; 23:20-3.
- Furio A, Brusco L, Cardinali D. Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study. J. Pineal Res. 2007; 43:404-409.
- Zaslavskaia R, Komarov F, Shakirova A, et al. Effect of moxonidine monotherapy and in combination with melatonin on hemodynamic parameters in patients with arterial hypertension. Klin Med. 2000; 78:41-44.
- Dowling G, Mastickb, Colling E, et al. Melatonin for sleep disturbances in Parkinson’s disease. Sleep Med. 2005; 6:459-466.
- Peled N, Shorer Z, Peled E, et al. Melatonin for sleep disturbances in Parkinson’s disease. Epilepsia. 2001;42(9):1208-1210.
- Dolberg O, Hirschmann S, Grunhaus H. Melatonin for the Treatment of Sleep Disturbances in Major Depressive Disorder Am. J.Psychiatry. 1998; 155:1119-1121.
- Leppamaki S, Partonen T, Vakkuri O, et al. Effect of controlled-release melatonin on sleep quality, mood, and quality of life in subjects with seasonal or weather-associated changes in mood and behavior. Eur. Neuropsychopharmacology. 2003; 13:137-145.
- Weiss M, Wasdell M, Bomben M, et al. Sleep Hygiene and Melatonin Treatment for Children and Adolescents with ADHD and Initial Insomnia. J. Am. Acad. Child Adolesc. Psychiatry. 2006; 45:512-519.
- Carminati G, Deriaz N, Bertschy G. Melatonin in the treatment of chronic sleep disorders in adults with autism: a ret rospective study. Swiss Med. Wkly. 2009; 139:293-296.
- Braam W, Smits M G, Didden R, et al. Exogenous melatonin for sleep problems in individuals with intellectual disability: a meta-analysis. Developmental Medicine and Child Neurology. 2009; 51:340-349.
- Mahmood D. Pleiotropic Effects of Melatonin. Drug Res (Stuttg). 2019; 69:65-74.
- Long R, Zhu Y, Zhou S. Therapeutic role of melatonin in migraine prophylaxis: A systematic review. Medicine (Baltimore). 2019;98: e14099.
- Lyon C, Langner S. PURLs: Consider melatonin for migraine prevention. J FamPract. 2017; 66:320-322.
- Lawson K. Is there a role for melatonin in fibromyalgia? AIMS Molecular Science, 2019;6:73-86.
- Miroddi M, Bruno R, Galletti F, et al. Clinical pharmacology of melatonin in the treatment of tinnitus: a review. Eur J ClinPharmacol. 2015; 71:263-70.
- Lundmark P, Pandi-Perumal S, Srinivasan V, et al. Role of melatonin in the eye and ocular dysfunctions. Visual Neuroscience, 2006; 23:853-862.
- Rosenstein R, Pandi-Perumal, S, Srinivasan V, et al. Melatonin as a therapeutic tool in ophthalmology: implications for glaucoma and uveitis. J. Pineal Res. 2010; 49:1–13.
- Awad-Alkoziv H. Melatonin and melanopsin in the eye: friends or foes? An Real Acad Farm. 2019; 85:49-59.
- Siah KT, Wong RK, Ho KY. Melatonin for the treatment of irritable bowel syndrome. World J Gastroenterol. 2014; 20:2492-2498.
- BahrampourJuybari K, Pourhanifeh MH, et al. Melatonin potentials against viral infections including COVID-19: Current evidence and new findings. Virus Res. 2020; 287:198108.
- Zhang R, Wang X, Ni L, et al. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 2020; 250:117583.
- Castillo RR, Quizon GRA, Juco MJM, et al. Melatonin as adjuvant treatment for coronavirus disease 2019 pneumonia patients requiring hospitalization (MAC-19 PRO): a case series. Melatonin Research. 2020; 3:297-310.
- Gonçalves AL, Martini Ferreira A, Ribeiro RT, et al. Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. J NeurolNeurosurg Psychiatry. 2016; 87:1127-1132.
- Peres MF, Zukerman E, da Cunha Tanuri F, et al. Melatonin, 3 mg, is effective for migraine prevention. Neurology. 2004; 63:757.
- Hurtuk A, Dome C, Holloman CH, et al. Melatonin: can it stop the ringing? Ann OtolRhinolLaryngol. 2011; 120:433-40.
- Ismail SA, Mowafi HA. Melatonin provides anxiolysis, enhances analgesia, decreases intraocular pressure, and promotes better operating conditions during cataract surgery under topical anesthesia. AnesthAnalg. 2009; 108:1146-1151.
- Samples JR, Krause G, Lewy AJ. Effect of melatonin on intraocular pressure. Curr Eye Res. 1988; 7:649-53.
- Role of Antihistamine and Leukotriene Receptor Antagonist in Allergic Rhinitis Management: Newer Perspectives
Authors
1 President- Medical & Regulatory Affairs, IN
2 Deputy General Manager- Medical, Scientific Department, IN
3 Manager- Scientific Department, Aristo Pharmaceuticals Private Limited, Mumbai, India., IN
Source
The Indian Practitioner, Vol 75, No 6 (2022), Pagination: 28-34Abstract
Allergic disorders are conditions induced by the immune system’s hypersensitivity to normally harmless chemicals known as allergens. The most common allergens include dust mites, pollution, grass pollens and food allergens such as milk, egg, soy, wheat, nut, or fish proteins. Allergic diseases include allergic rhinitis (AR), allergic asthma, urticaria, atopic dermatitis, contact allergies and food allergies. AR is the most common of all atopic diseases, afflicting 10%–30% of adults and up to 40% of children all over the world. The mechanisms underlying AR are highly complex and involve multiple immune cells, mediators and cytokines such as histamine and leukotrienes. It is characterized by nasal symptoms such as sneezing, nasal itching, rhinorrhea, and nasal congestion. It is also, associated with non-nasal symptoms such as watery eyes, redness in the eyes or inflammation. It has a significant effect on one’s health, as well as the quality of one’s sleep, work productivity and academic performance. The management of AR includes allergen avoidance, pharmacotherapy, and immunotherapy. Complete avoidance of allergens that trigger AR symptoms is not possible. Current pharmacologic options include antihistamines (oral and intranasal), Leukotriene Receptor Antagonists (LTRAs), Intranasal Corticosteroids (INCS), decongestants and oral and intranasal anticholinergics. Amongst other antihistamines, Bilastine has emerged as a new, non-sedating and well-tolerated antihistamine while Montelukast is an effective add-on LTRA option to an antihistamine with well-established literature in the management of moderate-severe AR. Immunotherapy is a treatment option for patients who have not responded to medication.
Keywords
Allergic rhinitis, antihistamines, LTRAs, montelukast, bilastineReferences
- Pawankar R, Mori S, Ozu C, Kimura S. Overview on the pathomechanisms of allergic rhinitis. Asia Pac. Allergy. 2011;1:157-167.
- Kim H, Bouchard J, Renzi P M. The link between allergic rhinitis and asthma: A role for antileukotrienes? Can Respir J.2008;15(2):91-98.
- Bhargava S, Sheth K, Bharathi MB, Dabholkar Y, Pendakur A, Desai A, et al. Indian guidelines on diagnosis and mange ment of Allergic Rhinitis- A consensus approach.
- Pawankar R, Canonica GW, Holgate ST, Lockey RF, Blaiss MS. World Allergy Organization (WAO) White Book on Allergy: Update. 2013.
- Chandrika D. Allergic rhinitis in India: an overview. Int J Otorhinolaryngol Head Neck Surg. 2017;3(1):1-6.
- Valovirta E. Pawankar R. Survey on the impact of comorbid allergic rhinitis in patients with asthma. BMC Pulm. Med.2006;6:1–10.
- Bjermer L, Westman M, Holmstrom M, Wickman MC. The complex pathophysiology of allergic rhinitis: Scientific rationale for the development of an alternative treatment option. Allergy, Asthma Clin. Immunol.2019;15:1–15.
- Giavina BP, Aun MV, Takejima P, Kalil J, Agondi RC. United airway disease: current perspectives. Journal of Asthma and Allergy.2016;9:93–100.
- Jaggi V, Dalal A, Ramesh BR, Tikkiwal S, Chaudhry A, Kothari N,et al. Coexistence of allergic rhinitis and asthma in Indian patients: The CARAS survey. Lung India.2019;36:411-6.
- Bergeron C, Qutayba H. Relationship between Asthma and Rhinitis: Epidemiologic, Pathophysiologic, and Therapeutic Aspects. Allergy, Asthma, and Clinical Immunology.2005; 1(2):81-87.
- Small P, Keith PK, Kim H. Allergic rhinitis. Allergy, Asthma and Clinical Immunology.2018;14(2):31-41.
- Heinzerling L, Mari A, Bergmann KC, Bresciani M, Burbach G, Darsow U, et al. The skin prick test – European standards. Clinical and Translational Allergy.2013;3:3.
- Min YG. The Pathophysiology, Diagnosis and Treatment of Allergic Rhinitis. Allergy, Asthma Immunol Res. 2010;2(2):6576.
- Pawankar R, Bunnag C, Chen Y, Fukuda T, Kim YY, Tuyet Le LT, et al. Allergic Rhinitis and its impact on asthma update (ARIA 2008) - Western and Asian-Pacific Perspective. Asia Pacific Journal of Allergy and Immunology.2009;27:237-243.
- Krouse JH. Allergic Rhinitis- Current Pharmacotherapy. Otolaryngol Clin N Am. 2008;41:347–358.
- Hossenbaccus L, Linton S, Garvey S, Ellis AK. Towards definitive management of allergic rhinitis: best use of new and established therapies. Allergy, Asthma Clin Immunol.2020;16:39.
- Ridolo E, Montagni M, Bonzana L, Incorvaia C, Canonica GW. Bilastine: New insight into antihistamine treatment. Clinical and Molecular Allergy.2015;13:1.
- Valk PJ, Simons RM, Valiente R, Labeaga L. Cognitive Performance Effects of Bilastine 20 mg During 6 Hours at 8000 ft Cabin Altitude. Aerospace Medicine and Human Performance. 2016;87(7):622-627.
- Horak F. Effectiveness of twice daily azelastine nasal spray in patients with seasonal allergic rhinitis. Therapeutics and Clinical Risk Management 2008;4(5):1009–1022.
- Yu Xu, Zhang J, Wang J. The Efficacy and Safety of Selective H1-Antihistamine versus Leukotriene Receptor Antagonist for SeasonalAllergic Rhinitis: A Meta-Analysis.PLOS ONE.2014;9(11):e112815.
- Okubo K, et al. Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study. Allergology International.2016:1-9.
- Kuna P, Bachert C, Nowacki Z, Cauwenbergew P, Agache I, Fouquert L, et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clinical & Experimental Allergy.2009;39:1338–1347.
- Bachert C, Kuna P, Sanquer F, Ivan P, Dimitrov V, Gorina M, et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy.2009: 64: 158–165.
- Rajput MS, Arain AA, Rajput AA, Mohammad A, Ghaffar S, et al. Effect of montelukast on the Symptom Severity Score of Allergic Rhinitis. Cureus12(3):e7403.
- Philip G, Malmstrom K, Hampel FC, Weinstein SF, LaForce CF, Ratner PH, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy. 2002;32:1020- 1028.